Persistence of Anti-SARS-CoV-2 Antibodies Following SARS-CoV-2 Infection
| Author | Somaieh Matin | en |
| Author | Nasrin Fouladi | en |
| Author | Vahid Asghariazar | en |
| Author | Saeideh Seyedbarghy | en |
| Author | Hassan Ghobadi | en |
| Author | Majid Eterafi | en |
| Author | Sajjad Barin | en |
| Author | Hadi Peeri Doghaheh | en |
| Author | Hamid Afzoun Khiavi | en |
| Author | Elham Safarzadeh | en |
| Orcid | Somaieh Matin [0000-0001-7026-9951] | en |
| Orcid | Nasrin Fouladi [0000-0002-9809-6711] | en |
| Orcid | Vahid Asghariazar [0000-0002-9809-6711] | en |
| Issued Date | 2026-06-30 | en |
| Abstract | Background: Since the first emergence of coronavirus disease 2019 (COVID-19) in China, elucidating the persistence and dynamics of antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has remained a major research priority. Objectives: To quantify serum titers of anti-SARS-CoV-2 IgM and IgG antibodies in patients with COVID-19 over a 9-month period. Methods: In this longitudinal study, blood samples were collected from 105 patients with COVID-19 who presented with mild to severe clinical manifestations at diagnosis and again at follow-up. Of these, 100 patients with complete serological data were included in the final analysis. Concentrations of anti-SARS-CoV-2-specific IgG and IgM antibodies in the collected serum samples were measured using an enzyme-linked immunosorbent assay (ELISA). Results: Of the 105 initially recruited patients, 100 (95.2%) had complete serological data and were included in the final analysis. Among all patients included in the final analysis (43 females and 57 males), 41% had severe manifestations, whereas the remainder had mild/moderate manifestations of the disease. Among all subjects, the median (interquartile range) serum IgM, baseline IgG, and follow-up IgG titers were 3.5, 10, and 4.4 cut-off index (COI), with IQRs of 5, 11.6, and 5.9, respectively. We found that approximately 81% of patients remained seropositive over the subsequent 9 months; however, the secondary IgG titer decreased from 10 to 4.4 COI relative to the primary IgG titer. Exploratory subgroup analyses suggested a slower decline in antibody levels among healthcare workers than among non-healthcare workers. However, in multivariable analysis, the baseline IgG level was the only independent predictor of antibody persistence at the 9-month follow-up. Conclusions: This study demonstrated that anti-SARS-CoV-2 antibody responses remained detectable in most patients approximately 9 months after infection. These findings provide preliminary evidence regarding the persistence of antibody responses and may have implications for vaccination strategies and the understanding of post-infection immunity. | en |
| DOI | https://doi.org/10.69107/jid-170350 | en |
| URI | https://brieflands.com/journals/jid/articles/170350 | en |
| Keyword | Antibody Levels | en |
| Keyword | Infection | en |
| Keyword | Coronavirus | en |
| Keyword | COVID-19 | en |
| Keyword | Immune Responses | en |
| Keyword | Healthcare Workers | en |
| Publisher | Brieflands | en |
| Title | Persistence of Anti-SARS-CoV-2 Antibodies Following SARS-CoV-2 Infection | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jid-30-2-170350-publish-pdf.pdf
- Size:
- 761.08 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF